Cargando…

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the polar metabolome and lipidome in 330 TNBC samples and 149 paired normal breast tissues to construct a large metabolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Yi, Ma, Ding, Yang, Yun-Song, Yang, Fan, Ding, Jia-Han, Gong, Yue, Jiang, Lin, Ge, Li-Ping, Wu, Song-Yang, Yu, Qiang, Zhang, Qing, Bertucci, François, Sun, Qiuzhuang, Hu, Xin, Li, Da-Qiang, Shao, Zhi-Ming, Jiang, Yi-Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061756/ https://www.ncbi.nlm.nih.gov/pubmed/35105939 http://dx.doi.org/10.1038/s41422-022-00614-0

Ejemplares similares

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
por: Jiang, Yi-Zhou, et al.
Publicado: (2020)

A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers
por: Chen, Qingwang, et al.
Publicado: (2022)

Molecular subtypes and precision treatment of triple-negative breast cancer
por: Zhao, Shen, et al.
Publicado: (2020)

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer
por: Wei, Jin-Li, et al.
Publicado: (2021)

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
por: Liu, Yin, et al.
Publicado: (2023)

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
por: Liu, Yi-Rong, et al.
Publicado: (2016)

NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: He, Xiangming, et al.
Publicado: (2021)

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
por: Liu, Zhixian, et al.
Publicado: (2018)

Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice
por: Zhang, Hang, et al.
Publicado: (2023)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Comprehensive evaluation of caloric restriction-induced changes in the metabolome profile of mice
por: Xie, Dadi, et al.
Publicado: (2022)

Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer
por: Ding, Jia-Han, et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer
por: Xu, Jiahui, et al.
Publicado: (2021)

Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression
por: Yang, Yun-Song, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells
por: Yang, Meng, et al.
Publicado: (2019)

Metabolomics Studies on Cytoplasmic Male Sterility during Flower Bud Development in Soybean
por: Ding, Xianlong, et al.
Publicado: (2019)

NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling
por: Zhang, Jianchao, et al.
Publicado: (2016)

Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database
por: Wang, Xiao-Xiao, et al.
Publicado: (2016)

Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing
por: Gong, Shasha, et al.
Publicado: (2020)

Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis
por: Shen, Li-wen, et al.
Publicado: (2021)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

Uncovering the molecular subtypes of triple-negative breast cancer with a noninvasive radiomic methodology
por: Su, Guan-Hua, et al.
Publicado: (2022)

Comprehensive Analysis of the Implication of PGRMC1 in Triple-Negative Breast Cancer
por: Xu, Xin, et al.
Publicado: (2021)

Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets
por: Zhang, Ying, et al.
Publicado: (2022)

Construction and Comprehensive Analysis of a ceRNA Network to Reveal Potential Novel Biomarkers for Triple-Negative Breast Cancer
por: Ma, Lifei, et al.
Publicado: (2020)

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer
por: He, Min, et al.
Publicado: (2017)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer
por: Chen, Yi-Yu, et al.
Publicado: (2020)

Comprehensive Analysis of TRP Channel–Related Genes in Patients With Triple-Negative Breast Cancer for Guiding Prognostic Prediction
por: Zhang, Haojie, et al.
Publicado: (2022)

The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs
por: Pan, Weijun, et al.
Publicado: (2022)

Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
por: Gui, Xinyu, et al.
Publicado: (2018)

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer
por: Jiang, Lin, et al.
Publicado: (2022)

Identification by Comprehensive Bioinformatics Analysis of KIF15 as a Candidate Risk Gene for Triple-Negative Breast Cancer
por: Sheng, Jiayu, et al.
Publicado: (2020)

Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
por: Zhou, Yi-Fan, et al.
Publicado: (2021)

Inositol monophosphatase 1 (IMPA1) promotes triple‐negative breast cancer progression through regulating mTOR pathway and EMT process
por: Yang, Shao‐Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k3bhsc6bhjji51pr2jqm368ppk